Trade bluebird bio, Inc. - BLUE CFD
Add to favourite- Summary
- Historical Data
Spread | 0.04 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 0.9 |
Open | 0.89 |
1-Year Change | -73.82% |
Day's Range | 0.87 - 0.9 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 24, 2024 | 0.90 | -0.07 | -7.22% | 0.97 | 1.00 | 0.89 |
Apr 23, 2024 | 0.95 | 0.01 | 1.06% | 0.94 | 1.03 | 0.94 |
Apr 22, 2024 | 0.93 | -0.07 | -7.00% | 1.00 | 1.01 | 0.91 |
Apr 19, 2024 | 1.00 | 0.07 | 7.53% | 0.93 | 1.01 | 0.92 |
Apr 18, 2024 | 0.93 | -0.01 | -1.06% | 0.94 | 0.98 | 0.90 |
Apr 17, 2024 | 0.95 | 0.01 | 1.06% | 0.94 | 1.01 | 0.93 |
Apr 16, 2024 | 0.97 | -0.04 | -3.96% | 1.01 | 1.05 | 0.96 |
Apr 15, 2024 | 1.02 | -0.07 | -6.42% | 1.09 | 1.10 | 1.00 |
Apr 12, 2024 | 1.09 | -0.05 | -4.39% | 1.14 | 1.17 | 1.06 |
Apr 11, 2024 | 1.15 | -0.03 | -2.54% | 1.18 | 1.20 | 1.13 |
Apr 10, 2024 | 1.18 | 0.02 | 1.72% | 1.16 | 1.19 | 1.15 |
Apr 9, 2024 | 1.24 | 0.09 | 7.83% | 1.15 | 1.24 | 1.14 |
Apr 8, 2024 | 1.15 | -0.07 | -5.74% | 1.22 | 1.22 | 1.14 |
Apr 5, 2024 | 1.21 | 0.02 | 1.68% | 1.19 | 1.25 | 1.17 |
Apr 4, 2024 | 1.21 | 0.03 | 2.54% | 1.18 | 1.25 | 1.16 |
Apr 3, 2024 | 1.17 | 0.01 | 0.86% | 1.16 | 1.20 | 1.15 |
Apr 2, 2024 | 1.19 | 0.00 | 0.00% | 1.19 | 1.23 | 1.15 |
Apr 1, 2024 | 1.22 | -0.03 | -2.40% | 1.25 | 1.28 | 1.21 |
Mar 28, 2024 | 1.25 | -0.10 | -7.41% | 1.35 | 1.40 | 1.23 |
Mar 27, 2024 | 1.35 | 0.17 | 14.41% | 1.18 | 1.37 | 1.14 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Bluebird Company profile
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.Industry: | Bio Therapeutic Drugs |
455 Grand Union Boulevard
SOMERVILLE
MASSACHUSETTS 02145
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com